A US study found a significantly higher cost of care associated with cirrhosis vs with heart failure or chronic obstructive pulmonary disease.

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

Jehangir Hospital continues to revolutionize healthcare in Pune, setting benchmarks in patient care and medical excellence.

Jehangir Hospital's Pulmonology Department sets new standards in healthcare with cutting-edge diagnostics and personalized ...

Policy experts say if the federal government cuts Medicaid by 10%, more than 100,000 San Diego County residents could lost ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...

Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

A recent study found that participants who practice mindfulness reported significantly less severe symptoms of anxiety, ...

The first line of pharmacological treatment for schizophrenia is antipsychotic medication. However, antipsychotic medications are ineffective in more than 30% of people with the disorder. This is ...